Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

The Centers for Medicare & Medicaid Services announced 15 new drugs it wants to lower the cost for, including popular, but ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

U.S. Health and Human Services Secretary Xavier Becerra says “this is a big deal.” Drug companies oppose the program.

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

The talks on drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices that ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare's list of medications that will be ...